한글목차

세계 지도상 위축(GA) 시장 규모는 2034년까지 연평균 15.6%의 성장률을 보일 것으로 예상됩니다.

시장 성장을 견인하는 사업자 간 제휴가 시장 성장을 견인

다양한 전문 지식, 자원 및 기술을 결합하여 혁신적인 치료법의 개발과 상용화를 가속화하기 위해 시장 참여자들 간의 협력 관계가 증가하고 있는 것이 시장 발전의 원동력이 되고 있습니다. 제휴를 통해 기업들은 연구개발에 따른 위험과 비용을 분담하고, 서로의 강점에 접근하여 경쟁력을 강화할 수 있습니다.

GA 치료에 따른 과제들이 시장 성장의 걸림돌로 작용할 가능성도 있습니다.

지도 위축(GA) 치료는 특히 의료 접근성이 제한적인 원격지에서는 발견과 치료가 지연되는 큰 문제에 직면해 있습니다. 눈 건강과 정기적인 검사에 대한 인식을 높이는 것이 중요합니다. 현재 GA 치료는 치료법이 없고, 효과가 제한적이며, 투여 횟수가 많고, 장애를 되돌릴 수 없는 등 여러 가지 장애물이 있습니다. 정확한 진단과 표적 치료를 위해서는 첨단 영상진단 기술과 유전자 연구가 필수적입니다. 유전자 치료와 줄기세포 치료 등 유망한 치료법이 개발 중이지만, 유효성 평가지표의 부재와 후기 단계 약물의 실패는 GA의 치료가 여전히 어렵다는 것을 강조하고 있습니다.

세계 지도상 위축(GA) 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 요인과 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별/지역별/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
• 영향 분석
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
• 규제 프레임워크
• 신흥 시장과 메가트렌드
• Porter의 Five Forces 분석
• PEST 분석

제4장 지도상위축(GA) 시장 분석 : 유형별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• Focal GA
• Multifocal GA
• Confluent GA
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제5장 지도상위축(GA) 시장 분석 : 약제별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• Pegcetacoplan(SYFOVRE)
• Avacincaptad pegol(IZERVAY)
• 기타
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제6장 지도상위축(GA) 시장 분석 : 투여 경로별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 유리체내 경로
• 정맥내 투여
• 기타
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제7장 지도상위축(GA) 시장 분석 : 유통 채널별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 병원 약국
• 소매 약국
• E-Commerce 약국
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제8장 지도상위축(GA) 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추이와 예측

제9장 북미의 지도상위축(GA) 시장 분석

제10장 유럽의 지도상위축(GA) 시장 분석

제11장 아시아의 지도상위축(GA) 시장 분석

제12장 기타 지역의 지도상위축(GA) 시장 분석

제13장 기업 개요

• 경쟁 구도
• 전략적 전망
• Alkeus Pharmaceuticals, Inc.
• Bausch+Lomb
• Ionis Pharmaceuticals
• Santen Pharmaceutical Co., Ltd.
• Astellas Pharma Inc.
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche Ltd.
• Apellis Pharmaceuticals
• AstraZeneca
• Johnson &Johnson

제14장 결론 및 제안

• Visiongain의 결론
• 시장 진출기업에 대한 제안

영문목차

The global Geographic Atrophy market is projected to grow at a CAGR of 15.6% by 2034

The Geographic Atrophy Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Collaborations Among Market Players are Driving the Market Growth

Rising collaborations amongst market players are driving market growth because they combine diverse expertise, resources, and technologies, accelerating the development and commercialisation of innovative treatments. Partnerships allow companies to share risks and costs associated with research and development, access each other's strengths, and enhance their competitive edge. On April 29, 2023, Astellas Pharma Inc. and Iveric Bio, Inc. announced a definitive agreement under which Astellas, through its subsidiary Berry Merger Sub, Inc.

Challenges Associated with GA Treatment Likely to Hamper Market Growth

Geographic atrophy (GA) treatment faces significant challenges, particularly in remote areas with limited healthcare access, leading to delayed detection and treatment. Raising awareness about eye health and regular exams is crucial. Current GA treatments are hindered by the lack of a cure, limited effectiveness, frequent administration, and inability to reverse damage. Advanced imaging technologies and genetic research are essential for accurate diagnosis and targeted therapies. Promising treatments, including gene and stem cell therapies, are in development, but the lack of validated endpoints and failures of late-stage drugs underscore the ongoing difficulties in treating GA.

What Questions Should You Ask before Buying a Market Research Report?

• How is the geographic atrophy market evolving?
• What is driving and restraining the geographic atrophy market?
• How will each geographic atrophy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each geographic atrophy submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading geographic atrophy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the geographic atrophy projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of geographic atrophy projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the geographic atrophy market?
• Where is the geographic atrophy market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the geographic atrophy market today, and over the next 10 years:

• Our 218-page report provides 80 tables and 144 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
• Forecasts to 2034 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising geographic atrophy prices and recent developments.

Segments Covered in the Report

• Type
• Focal GA
• Multifocal GA
• Confluent GA
• Drugs
• Pegcetacoplan (SYFOVRE)
• Avacincaptad pegol (IZERVAY)
• Others
• Route of Administration
• Intravitreal Route
• Intravenous Route
• Others
• Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 10 leading national markets:

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Rest of Asia Pacific
• Rest of the World (RoW)

The report also includes profiles for some of the leading companies in the Geographic Atrophy Market, 2024 to 2034, with a focus on this segment of these companies'operations.

• Leading companies profiled in the report
• Alkeus Pharmaceuticals, Inc.
• Apellis Pharmaceuticals
• Astellas Pharma Inc.
• AstraZeneca
• Bausch + Lomb
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche Ltd.
• Ionis Pharmaceuticals
• Johnson & Johnson
• Santen Pharmaceutical Co., Ltd.

Overall world revenue for Geographic Atrophy Market, 2024 to 2034 in terms of value the market will surpass US$4,500 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

• How will the Geographic Atrophy Market, 2024 to 2034 report help you?
• In summary, our 210+ page report provides you with the following knowledge:
• Revenue forecasts to 2034 for Geographic Atrophy Market, 2024 to 2034 Market, with forecasts for type, drugs, route of administration, and distribution channel, each forecast at a global and regional level - discover the industry' prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 10 key national markets - See forecasts for the Geographic Atrophy Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, and RoW. Also forecasted is the market in the U.S., Canada, Germany, France, UK, Italy, France, Spain, China, India, and Japan among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the Geographic Atrophy Market, 2024 to 2034.
• Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
• Information found nowhere else
• With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Geographic Atrophy Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Geographic Atrophy Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
• 3.3 Impact Analysis
  • 3.3.1 Market Driving Factors
    • 3.3.1.1 New Product Launches is Driving the Market Growth
    • 3.3.1.2 Rising Geriatric Population
    • 3.3.1.3 Growing Prevalence of Geographic Atrophy
  • 3.3.2 Market Restraining Factors
    • 3.3.2.1 High Cost of Novel Drugs is Restraining the Growth of the GA Market
    • 3.3.2.2 Challenges Associated with the Geographic Atrophy Treatment
  • 3.3.3 Market Opportunities
    • 3.3.3.1 Promising Product Pipeline
    • 3.3.3.2 Collaborations Amongst Market Players
    • 3.3.3.3 Increase in R&D Investments by Pharmaceutical & Biopharmaceutical Companies
• 3.4 Regulatory Framework
• 3.5 Emerging Markets and Megatrends
• 3.6 Porter's Five Forces Analysis
  • 3.6.1 Bargaining Power of Suppliers
  • 3.6.2 Bargaining Power of Buyers
  • 3.6.3 Competitive Rivalry
  • 3.6.4 Threat from Substitutes
  • 3.6.5 Threat of New Entrants
• 3.7 PEST Analysis

4 Geographic Atrophy Market Analysis by Type

• 4.1 Key Findings
• 4.2 Type Segment: Market Attractiveness Index
• 4.3 Geographic Atrophy Market Size Estimation and Forecast by Type
• 4.4 Focal GA
  • 4.4.1 Market Size by Region, 2024-2034 (US$ Million)
  • 4.4.2 Market Share by Region, 2024 & 2034 (%)
• 4.5 Multifocal GA
  • 4.5.1 Market Size by Region, 2024-2034 (US$ Million)
  • 4.5.2 Market Share by Region, 2024 & 2034 (%)
• 4.6 Confluent GA
  • 4.6.1 Market Size by Region, 2024-2034 (US$ Million)
  • 4.6.2 Market Share by Region, 2024 & 2034 (%)

5 Geographic Atrophy Market Analysis by Drugs

• 5.1 Key Findings
• 5.2 Drugs Segment: Market Attractiveness Index
• 5.3 Geographic Atrophy Market Size Estimation and Forecast by Drugs
• 5.4 Pegcetacoplan (SYFOVRE)
  • 5.4.1 Market Size by Region, 2024-2034 (US$ Million)
  • 5.4.2 Market Share by Region, 2024 & 2034 (%)
• 5.5 Avacincaptad pegol (IZERVAY)
  • 5.5.1 Market Size by Region, 2024-2034 (US$ Million)
  • 5.5.2 Market Share by Region, 2024 & 2034 (%)
• 5.6 Others
  • 5.6.1 Market Size by Region, 2024-2034 (US$ Million)
  • 5.6.2 Market Share by Region, 2024 & 2034 (%)

6 Geographic Atrophy Market Analysis by Route of Administration

• 6.1 Key Findings
• 6.2 Route of Administration Segment: Market Attractiveness Index
• 6.3 Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
• 6.4 Intravitreal Route
  • 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
  • 6.4.2 Market Share by Region, 2024 & 2034 (%)
• 6.5 Intravenous Route
  • 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
  • 6.5.2 Market Share by Region, 2024 & 2034 (%)
• 6.6 Others
  • 6.6.1 Market Size by Region, 2024-2034 (US$ Million)
  • 6.6.2 Market Share by Region, 2024 & 2034 (%)

7 Geographic Atrophy Market Analysis by Distribution Channel

• 7.1 Key Findings
• 7.2 Distribution Channel Segment: Market Attractiveness Index
• 7.3 Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
• 7.4 Hospital Pharmacies
  • 7.4.1 Market Size by Region, 2024-2034 (US$ Million)
  • 7.4.2 Market Share by Region, 2024 & 2034 (%)
• 7.5 Retail Pharmacies
  • 7.5.1 Market Size by Region, 2024-2034 (US$ Million)
  • 7.5.2 Market Share by Region, 2024 & 2034 (%)
• 7.6 E-Commerce Pharmacies
  • 7.6.1 Market Size by Region, 2024-2034 (US$ Million)
  • 7.6.2 Market Share by Region, 2024 & 2034 (%)

8 Geographic Atrophy Market Analysis by Region

• 8.1 Key Findings
• 8.2 Regional Market Size Estimation and Forecast

9 North America Geographic Atrophy Market Analysis

• 9.1 Key Findings
• 9.2 North America Geographic Atrophy Market Attractiveness Index
• 9.3 North America Geographic Atrophy Market by Country, 2024, 2029 & 2034 (US$ Million)
• 9.4 North America Geographic Atrophy Market Size Estimation and Forecast by Country
• 9.5 North America Geographic Atrophy Market Size Estimation and Forecast by Type
• 9.6 North America Geographic Atrophy Market Size Estimation and Forecast by Drugs
• 9.7 North America Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
• 9.8 North America Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
• 9.9 U.S. Geographic Atrophy Market Analysis
• 9.10 Canada Geographic Atrophy Market Analysis

10 Europe Geographic Atrophy Market Analysis

• 10.1 Key Findings
• 10.2 Europe Geographic Atrophy Market Attractiveness Index
• 10.3 Europe Geographic Atrophy Market by Country, 2024, 2029 & 2034 (US$ Million)
• 10.4 Europe Geographic Atrophy Market Size Estimation and Forecast by Country
• 10.5 Europe Geographic Atrophy Market Size Estimation and Forecast by Type
• 10.6 Europe Geographic Atrophy Market Size Estimation and Forecast by Drugs
• 10.7 Europe Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
• 10.8 Europe Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
• 10.9 Germany Geographic Atrophy Market Analysis
• 10.10 UK Geographic Atrophy Market Analysis
• 10.11 France Geographic Atrophy Market Analysis
• 10.12 Italy Geographic Atrophy Market Analysis
• 10.13 Spain Geographic Atrophy Market Analysis
• 10.14 Rest of Europe Geographic Atrophy Market Analysis

11 Asia Geographic Atrophy Market Analysis

• 11.1 Key Findings
• 11.2 Asia Geographic Atrophy Market Attractiveness Index
• 11.3 Asia Geographic Atrophy Market by Country, 2024, 2029 & 2034 (US$ Million)
• 11.4 Asia Geographic Atrophy Market Size Estimation and Forecast by Country
• 11.5 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Type
• 11.6 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Drugs
• 11.7 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
• 11.8 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
• 11.9 Japan Geographic Atrophy Market Analysis
• 11.10 China Geographic Atrophy Market Analysis
• 11.11 India Geographic Atrophy Market Analysis
• 11.12 Rest of Asia Geographic Atrophy Market Analysis

12 Rest of World Geographic Atrophy Market Analysis

• 12.1 Key Findings
• 12.2 Rest of World Geographic Atrophy Market Size Estimation and Forecast by Type
• 12.3 Rest of World Geographic Atrophy Market Size Estimation and Forecast by Drugs
• 12.4 Rest of World Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
• 12.5 Rest of World Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel

13 Company Profiles

• 13.1 Company Share Analysis, 2023
• 13.2 Strategic Outlook
• 13.3 Alkeus Pharmaceuticals, Inc.
  • 13.3.1 Company Snapshot
  • 13.3.2 Company Overview
  • 13.3.3 Product Benchmarking
  • 13.3.4 Strategic Outlook
  • 13.3.5 SWOT Analysis
• 13.4 Bausch + Lomb
  • 13.4.1 Company Snapshot
  • 13.4.2 Company Overview
  • 13.4.3 Financial Analysis
    • 13.4.3.1 Net Revenue, 2019-2023
    • 13.4.3.2 R&D, 2019-2023
    • 13.4.3.3 Regional Market Shares, 2023
    • 13.4.3.4 Business Segment Market Shares, 2023
  • 13.4.4 Product Benchmarking
  • 13.4.5 Strategic Outlook
  • 13.4.6 SWOT Analysis
• 13.5 Ionis Pharmaceuticals
  • 13.5.1 Company Snapshot
  • 13.5.2 Company Overview
  • 13.5.3 Financial Analysis
    • 13.5.3.1 Net Revenue, 2019-2023
    • 13.5.3.2 R&D, 2019-2023
    • 13.5.3.3 Regional Market Shares, 2023
  • 13.5.4 Product Benchmarking
  • 13.5.5 Strategic Outlook
• 13.6 Santen Pharmaceutical Co., Ltd.
  • 13.6.1 Company Snapshot
  • 13.6.2 Company Overview
  • 13.6.3 Financial Analysis
    • 13.6.3.1 Net Revenue, 2019-2023
    • 13.6.3.2 R&D, 2019-2023
    • 13.6.3.3 Regional Market Shares, 2023
  • 13.6.4 Product Benchmarking
  • 13.6.5 Strategic Outlook
• 13.7 Astellas Pharma Inc.
  • 13.7.1 Company Snapshot
  • 13.7.2 Company Overview
  • 13.7.3 Financial Analysis
    • 13.7.3.1 Net Revenue, 2019-2023
    • 13.7.3.2 R&D, 2019-2023
    • 13.7.3.3 Regional Market Shares, 2023
  • 13.7.4 Product Benchmarking
  • 13.7.5 Strategic Outlook
  • 13.7.6 SWOT Analysis
• 13.8 Boehringer Ingelheim International GmbH
  • 13.8.1 Company Snapshot
  • 13.8.2 Company Overview
  • 13.8.3 Financial Analysis
    • 13.8.3.1 Net Revenue, 2019-2023
    • 13.8.3.2 R&D, 2019-2023
    • 13.8.3.3 Regional Market Shares, 2023
    • 13.8.3.4 Business Segment Market Shares, 2023
  • 13.8.4 Product Benchmarking
  • 13.8.5 Strategic Outlook
  • 13.8.6 SWOT Analysis
• 13.9 F. Hoffmann-La Roche Ltd.
  • 13.9.1 Company Snapshot
  • 13.9.2 Company Overview
  • 13.9.3 Financial Analysis
    • 13.9.3.1 Net Revenue, 2019-2023
    • 13.9.3.2 R&D, 2019-2023
    • 13.9.3.3 Business Segment Market Shares, 2023
  • 13.9.4 Product Benchmarking
  • 13.9.5 Strategic Outlook
  • 13.9.6 SWOT Analysis
• 13.10 Apellis Pharmaceuticals
  • 13.10.1 Company Snapshot
  • 13.10.2 Company Overview
  • 13.10.3 Financial Analysis
    • 13.10.3.1 Net Revenue, 2019-2023
    • 13.10.3.2 R&D, 2019-2023
    • 13.10.3.3 Business Segment Market Shares, 2023
  • 13.10.4 Product Benchmarking
  • 13.10.5 Strategic Outlook
  • 13.10.6 SWOT Analysis
• 13.11 AstraZeneca
  • 13.11.1 Company Snapshot
  • 13.11.2 Company Overview
  • 13.11.3 Financial Analysis
    • 13.11.3.1 Net Revenue, 2019-2023
    • 13.11.3.2 R&D, 2019-2023
    • 13.11.3.3 Regional Market Shares, 2023
    • 13.11.3.4 Business Segment Market Shares, 2023
  • 13.11.4 Product Benchmarking
  • 13.11.5 Strategic Outlook
  • 13.11.6 SWOT Analysis
• 13.12 Johnson & Johnson
  • 13.12.1 Company Snapshot
  • 13.12.2 Company Overview
  • 13.12.3 Financial Analysis
    • 13.12.3.1 Net Revenue, 2019-2023
    • 13.12.3.2 R&D, 2019-2023
    • 13.12.3.3 Regional Market Shares, 2023
    • 13.12.3.4 Business Segment Market Shares, 2023
  • 13.12.4 Product Benchmarking
  • 13.12.5 Strategic Outlook

14 Conclusion and Recommendations

• 14.1 Concluding Remarks from Visiongain
• 14.2 Recommendations for Market Players